Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer
Oxidative Medicine and Cellular Longevity · 31.01.2023 · 2023 · 1-21
DOI: 10.1155/2023/1367938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oxidative Medicine and Cellular Longevity, erschienen am 31.01.2023. Verfasst von Chen Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Ferroptosis, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI, such as gefitinib) in lung cancer continues to be a major problem. Recent studies have shown the promise of ferroptosis-inducing therapy in EGFR-TKI resistant cancer, but have not been translated into clinical benefits. Here, we identified carbonic anhydrase IX (CA9) was upregulated in gefitinib-resistant lung cancer. Then we measured the cell viability, intracellular reactive oxygen species (ROS) levels, and labile iron levels after the treatment of ferroptosis inducer erastin. We found that CA9 confers resistance to ferroptosis-inducing drugs. Mechanistically, CA9 is involved in the inhibition of transferrin endocytosis and the stabilization of ferritin, leading to resistance to ferroptosis. Targeting CA9 promotes iron uptake and release, thus triggering gefitinib-resistant cell ferroptosis. Notably, CA9 inhibitor enhances the ferroptosis-inducing effect of cisplatin on gefitinib-resistant cells, thus eliminating resistant cells in heterogeneous tumor tissues. Taken together, CA9-targeting therapy is a promising approach to improve the therapeutic effect of gefitinib-resistant lung cancer by inducing ferroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, China.
ORCID-Profile: Chen Zhang, Xiyi Lu, Xinyin Liu, Jiali Xu, Jun Li, Tianyu Qu, Jiali Dai, Renhua Guo
Förderung
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Zhang, C., Lu, X., Liu, X., Xu, J., Li, J., Qu, T., Dai, J., & Guo, R. (2023). Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer. Oxidative Medicine and Cellular Longevity, 2023, 1-21. https://doi.org/10.1155/2023/1367938
Vancouver
Zhang C, Lu X, Liu X, Xu J, Li J, Qu T, et al. Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer. Oxidative Medicine and Cellular Longevity. 2023;2023:1-21. doi:10.1155/2023/1367938
BibTeX
@article{Zhang2023,
author = {Zhang, Chen and Lu, Xiyi and Liu, Xinyin and Xu, Jiali and Li, Jun and Qu, Tianyu and Dai, Jiali and Guo, Renhua},
title = {Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer},
journal = {Oxidative Medicine and Cellular Longevity},
year = {2023},
volume = {2023},
pages = {1--21},
doi = {10.1155/2023/1367938}
}
EUVIMED